Treatment Sequencing in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC) in Japan

被引：0
|
作者：
Goto, Y. [1 ]
Yamamoto, N. [2 ]
Masters, E. [3 ]
Kikkawa, H. [4 ]
Mardekian, J. [3 ]
Wiltshire, R. [5 ]
Togo, K. [4 ]
Ma, H. [6 ]
Ohe, Y. [1 ]
机构：
[1] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan
[2] Wakayama Med Univ, Dept Internal Med, Wakayama, Japan
[3] Pfizer Inc, New York, NY USA
[4] Pfizer Japan Inc, Tokyo, Japan
[5] Pfizer Inc, Tadworth, England
[6] Univ Michigan, Sch Publ Hlth, Ann Arbor, MI 48109 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
ALK-positive NSCLC; treatment sequencing; tyrosine kinase inhibitor;
D O I：
10.1016/j.jtho.2018.08.1590
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.01-30
引用
收藏
页码：S878 / S879
页数：2
相关论文
共 50 条
  • [1] Ensartinib in Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Patients: Updated Data
    Leal, T.
    Wakelee, H.
    Reckamp, K.
    Waqar, S.
    Patel, S.
    Blumenschein, G.
    Neal, J.
    Harrow, K.
    Holzhausen, A.
    Liang, C.
    Dukart, G.
    Horn, L.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : S156 - S156
  • [2] Ceritinib for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer
    Landi, Lorenza
    Cappuzzo, Federico
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (02) : 203 - 214
  • [3] SYSTEMATIC LITERATURE REVIEW (SLR) OF SEQUENCING OF ANAPLASTIC LYMPHOMA KINASE (ALK) INHIBITORS IN ALK-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC)
    Barrows, S. M.
    Wright, K.
    Copley-Merriman, C.
    Kaye, J. A.
    Chioda, M. D.
    Wiltshire, R.
    Torgersen, K. M.
    Masters, E. T.
    VALUE IN HEALTH, 2018, 21 : S49 - S50
  • [4] Intracranial activity of ensartinib in patients with anaplastic lymphoma kinase positive (ALK plus ) non-small cell lung cancer (NSCLC)
    Wakelee, H.
    Reckamp, K. L.
    Leal, T. A.
    Patel, S. P.
    Blumenschein, G.
    Shum, E.
    Nieva, J.
    Oxnard, G.
    Sanborn, R. E.
    Waqar, S.
    Zeman, K.
    Dukart, G.
    Harrow, K.
    Liang, C.
    Holzhausen, A.
    Horn, L.
    ANNALS OF ONCOLOGY, 2018, 29
  • [5] The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)
    Golding, Brandon
    Luu, Anita
    Jones, Robert
    Viloria-Petit, Alicia M.
    MOLECULAR CANCER, 2018, 17
  • [6] The function and therapeutic targeting of anaplastic lymphoma kinase (ALK) in non-small cell lung cancer (NSCLC)
    Brandon Golding
    Anita Luu
    Robert Jones
    Alicia M. Viloria-Petit
    Molecular Cancer, 17
  • [7] Expression of anaplastic lymphoma kinase (ALK) in patients with non-small cell lung cancer (NSCLC) in the South of Russia.
    Novikova, Inna Arnoldovna
    Nepomnyashchaya, Evgeniya M.
    Maksimov, Aleksey Yurievich
    Ulianova, Elena Petrovna
    Lazutin, Yury N.
    Anistratov, Pavel A.
    Pyltsin, Sergey P.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] ALKConnect: An Anaplastic Lymphoma Kinase Positive (ALK plus ) Non-Small Cell Lung Cancer (NSCLC) Patient Insights Network
    Lin, H.
    Pan, X.
    Huang, H.
    Salvatore, G.
    Clarke, S.
    West, H.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S617 - S617
  • [9] Frequency of anaplastic lymphoma kinase (ALK) positive tumors among African American non-small cell lung cancer (NSCLC) patients.
    Gadgeel, Shirish M.
    Cote, Michele L.
    Bepler, Gerold
    Murphy, Valerie
    Malysa, Agnes
    Wozniak, Antoinette J.
    Sukari, Ammar
    Schwartz, Ann G.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] Visual effects in anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib.
    Salgia, Ravi
    Solomon, Benjamin J.
    Shaw, Alice Tsang
    Camidge, D. Ross
    Evans, Tracey L.
    Kim, Dong-Wan
    Shi, Yuankai
    Han, Ji-Youn
    De Pas, Tommaso Martino
    Ou, Sai-Hong Ignatius
    Bartlett, Cynthia Huang
    Wilner, Keith D.
    Reisman, Arlene
    Iyer, Shrividya
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345